| scholarly article | Q13442814 |
| P2093 | author name string | B Svensson | |
| BARFOT Study Group | |||
| I Hafström | |||
| K Forslind | |||
| M Ahlmén | |||
| K Eberhardt | |||
| P2860 | cites work | How to interpret radiological progression in randomized clinical trials? | Q78739137 |
| Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies | Q24564876 | ||
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis | Q28345031 | ||
| Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis | Q33564689 | ||
| Associations of HLA-DRB and -DQB genes with two and five year outcome in rheumatoid arthritis | Q33578632 | ||
| The links between joint damage and disability in rheumatoid arthritis | Q33867923 | ||
| Early inflammatory polyarthritis: results from the Norfolk Arthritis Register with a review of the literature. II. Outcome at three years | Q34032150 | ||
| Prognostic factors in early rheumatoid arthritis | Q34042716 | ||
| Influence of cigarette smoking on disease outcome in rheumatoid arthritis | Q34531132 | ||
| Autoantibodies predicting the outcome of rheumatoid arthritis: evaluation in two subsets of patients according to severity of radiographic damage | Q35546969 | ||
| Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis | Q35550461 | ||
| An eight year prospective study of outcome prediction by antiperinuclear factor and antikeratin antibodies at onset of rheumatoid arthritis | Q35551809 | ||
| Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage | Q35552357 | ||
| Factors predicting outcome of rheumatoid arthritis: results of a followup study | Q41072217 | ||
| Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films | Q41513883 | ||
| Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. | Q41824468 | ||
| The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis | Q42631739 | ||
| Independent association of rheumatoid factor and the HLA-DRB1 shared epitope with radiographic outcome in rheumatoid arthritis | Q42655132 | ||
| The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide | Q44791267 | ||
| How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis | Q57789144 | ||
| Identification of the HLA-DRB1*04, -DRB1*07, and -DRB1*09 alleles by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours | Q67521659 | ||
| Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients | Q67546236 | ||
| Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire | Q67962680 | ||
| The effect of HLA-DRB1 genes, rheumatoid factor, and treatment on radiographic disease progression in rheumatoid arthritis over 6 years | Q73228725 | ||
| Antifilaggrin autoantibodies in early rheumatoid arthritis | Q73229330 | ||
| Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rheumatic Farmacotherapy | Q74312812 | ||
| Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study | Q74384496 | ||
| Antifilaggrin antibodies in early rheumatoid arthritis may predict radiological progression | Q74571107 | ||
| Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis | Q74714901 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| rheumatoid arthritis | Q187255 | ||
| P304 | page(s) | 1090-1095 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). | |
| P478 | volume | 63 |
| Q37076880 | A Contra Capture Protein Array Platform for Studying Post-translationally Modified (PTM) Auto-antigenomes |
| Q53797847 | A Molecular Analysis of the Shared Epitope Hypothesis: Binding of Arthritogenic Peptides to DRB1*04 Alleles. |
| Q90354326 | A Swedish register-based, long-term inception cohort study of patients with rheumatoid arthritis - results of clinical relevance |
| Q35868959 | A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for autoantibody production in rheumatoid arthritis |
| Q36534242 | A study on FoxP3 and Tregs in paired samples of peripheral blood and synovium in rheumatoid arthritis |
| Q35207886 | A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis |
| Q36183852 | ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome? |
| Q39061558 | Abatacept reduces disease activity and ultrasound power Doppler in ACPA-negative undifferentiated arthritis: a proof-of-concept clinical and imaging study |
| Q30656861 | Alcohol consumption is associated with lower self-reported disease activity and better health-related quality of life in female rheumatoid arthritis patients in Sweden: data from BARFOT, a multicenter study on early RA |
| Q47175280 | An increased concentration of receptor activator of nuclear factor kappa-B ligand pre-dates the onset of rheumatoid arthritis |
| Q42780638 | Analysis of serum immune markers in seropositive and seronegative rheumatoid arthritis and in high-risk seropositive arthralgia patients |
| Q47875926 | Anti-CCP antibodies are not a marker of severity in established rheumatoid arthritis: a magnetic resonance imaging study |
| Q35067205 | Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis |
| Q37163146 | Anti-CCP antibody in patients with established rheumatoid arthritis: Does it predict adverse cardiovascular profile? |
| Q82594480 | Anti-agalactosyl IgG antibodies in Thai patients with rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis |
| Q42643869 | Anti-carbamylated protein antibodies in rheumatoid arthritis patients and their association with rheumatoid factor |
| Q38857820 | Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review |
| Q37624583 | Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis |
| Q34635933 | Anti-citrulline antibodies in the diagnosis and prognosis of rheumatoid arthritis: evolving concepts |
| Q42036955 | Anti-cyclic citrullinated Peptide antibody: an early diagnostic and prognostic biomarker of rheumatoid arthritis |
| Q37312583 | Anti-cyclic citrullinated peptide antibodies--activity markers in rheumatoid arthritis. |
| Q81470939 | Anti-cyclic citrullinated peptide antibody in rheumatic diseases other than rheumatoid arthritis |
| Q92524356 | Anti-cyclic citrullinated peptide antibody is highly associated with rheumatoid factor and radiological defects in rheumatoid arthritis patients |
| Q51155261 | Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. |
| Q34244715 | Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis |
| Q90355984 | Antibodies against citrullinated peptides are associated with clinical and radiological outcomes in patients with early rheumatoid arthritis: a prospective longitudinal inception cohort study |
| Q39574748 | Antibodies to a new viral citrullinated peptide, VCP2: fine specificity and correlation with anti-cyclic citrullinated peptide (CCP) and anti-VCP1 antibodies. |
| Q34650192 | Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis |
| Q36740473 | Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis |
| Q33893385 | Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance |
| Q24812184 | Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis |
| Q39042536 | Anticyclic citrullinated peptide antibody and rheumatoid factor in south Tunisian patients with rheumatoid arthritis: association with disease activity and severity. |
| Q38812946 | Antigen arrays for profiling autoantibody repertoires |
| Q35605542 | Aspects of early arthritis. What determines the evolution of early undifferentiated arthritis and rheumatoid arthritis? An update from the Norfolk Arthritis Register |
| Q36111299 | Assessment of synovitis to predict bone erosions in rheumatoid arthritis. |
| Q36657901 | Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial |
| Q42608056 | Association of tobacco exposure and reduction of radiographic progression in early rheumatoid arthritis: results from a French multicenter cohort |
| Q36171863 | Associations between the PTPN22 1858C->T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study |
| Q36639920 | Associations of autoantibodies, autoimmune risk alleles, and clinical diagnoses from the electronic medical records in rheumatoid arthritis cases and non-rheumatoid arthritis controls |
| Q83007682 | Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA |
| Q35934700 | Autoantibodies to citrullinated (poly)peptides: a key diagnostic and prognostic marker for rheumatoid arthritis |
| Q79739232 | Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis |
| Q39933222 | Autoantibodies to human citrullinated fibrinogen and their subfamilies to the α36-50Cit and β60-74Cit fibrin peptides similarly predict radiographic damages: a prospective study in the French ESPOIR cohort of very early arthritides. |
| Q35555021 | Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis |
| Q24627677 | Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies |
| Q37761911 | Biomarkers for rheumatoid arthritis: making it personal |
| Q35953570 | Cigarette smoking and radiographic progression in rheumatoid arthritis |
| Q37318673 | Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis. |
| Q37690057 | Clinical correlations with Porphyromonas gingivalis antibody responses in patients with early rheumatoid arthritis |
| Q44848141 | Clinical features and independent predictors in the further development of rheumatoid arthritis in undifferentiated arthritis |
| Q55166388 | Clinical management of seronegative and seropositive rheumatoid arthritis: A comparative study. |
| Q35096891 | Clinical predictors of erosion-free status in rheumatoid arthritis: a prospective cohort study |
| Q82397612 | Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis |
| Q84040588 | Contribution of HLA-DRB1*04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis |
| Q33893960 | Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients |
| Q50210105 | Defining the proteomic landscape of rheumatoid arthritis: progress and prospective clinical applications |
| Q35644094 | Detection of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis patients undergoing total knee arthroplasty. |
| Q85653646 | Determination of Anticyclic Citrullinated Peptide Based on Biotin-Streptavidin-Amplified Time-Resolved Fluoroimmunoassay |
| Q37083373 | Diagnostic accuracy of immunoassays for the detection of antibodies to citrullinated proteins |
| Q24675281 | Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review |
| Q37453967 | Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis. |
| Q36960532 | Diagnostic performance and predictive value of rheumatoid factor, anti-cyclic-citrullinated peptide antibodies and HLA-DRB1 locus genes in rheumatoid arthritis |
| Q57753485 | Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of likelihood ratios |
| Q40976667 | Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis |
| Q80188767 | Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis |
| Q35620317 | Diagnostic properties of metabolic perturbations in rheumatoid arthritis |
| Q46712282 | Diagnostic value and clinical significance of anti-CCP in patients with advanced rheumatoid arthritis. |
| Q35808002 | Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis |
| Q39834837 | Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES |
| Q24812995 | Does a positive anti-CCP test identify a distinct arthritis entity? |
| Q35638360 | EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). |
| Q28083506 | Early biomarkers of joint damage in rheumatoid and psoriatic arthritis |
| Q36563395 | Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials |
| Q34460622 | Efficacy of three ELISA measurements of anti-cyclic citrullinated peptide antibodies in the early diagnosis of rheumatoid arthritis |
| Q35062205 | Electronic medical records for discovery research in rheumatoid arthritis |
| Q30390882 | Extensive Citrullination Promotes Immunogenicity of HSP90 through Protein Unfolding and Exposure of Cryptic Epitopes |
| Q33637585 | Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients |
| Q53688843 | Fcγ receptor-mediated influx of S100A8/A9-producing neutrophils as inducer of bone erosion during antigen-induced arthritis. |
| Q47679282 | Galectin-3 is Persistently Increased in Early Rheumatoid Arthritis (RA) and Associates with Anti-CCP Seropositivity and MRI Bone Lesions, While Early Fibrosis Markers Correlate with Disease Activity. |
| Q39908195 | Hand bone loss measured by digital X-ray radiogrammetry is a predictor of joint damage in early rheumatoid arthritis |
| Q53745420 | Health assessment questionnaire-disability index (HAQ-DI) score at the start of biological disease-modifying antirheumatic drug (bDMARD) therapy is associated with radiographic progression of large joint damage in patients with rheumatoid arthritis. |
| Q35760039 | High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis |
| Q38719851 | High titer of anti-citrullinated peptide antibody is a risk factor for severe carotid atherosclerotic plaque in patients with rheumatoid arthritis: the TOMORROW study |
| Q35614906 | How does age at onset influence the outcome of autoimmune diseases? |
| Q38689030 | Human Leukocyte Antigen Shared Epitope and Inflammation, Cardiovascular Disease, Cancer, and Mortality Among Postmenopausal Women in the Women's Health Initiative Rheumatoid Arthritis Study |
| Q24813085 | Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis |
| Q33815168 | Identification of natural bispecific antibodies against cyclic citrullinated peptide and immunoglobulin G in rheumatoid arthritis |
| Q34897560 | Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells |
| Q35825343 | Improved serological detection of rheumatoid arthritis: a highly antigenic mimotope of carbonic anhydrase III selected in a murine model by phage display. |
| Q35082791 | In patients with early inflammatory polyarthritis, ACPA positivity, younger age and inefficacy of the first non-biological DMARD are predictors for receiving biological therapy: results from the Norfolk Arthritis Register. |
| Q39797546 | Incidence rate of falls and its risk factors in patients with rheumatoid arthritis compared to controls: Four years of the TOMORROW study |
| Q43187116 | Increased expression of proto-oncogene survivin predicts Joint destruction and persistent disease activity in early rheumatoid arthritis |
| Q33608900 | Increased galectin-3 may serve as a serologic signature of pre-rheumatoid arthritis while markers of synovitis and cartilage do not differ between early undifferentiated arthritis subsets. |
| Q80141033 | Increased prevalence of anti-third generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome |
| Q33873636 | Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study |
| Q55018924 | Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort. |
| Q36245951 | Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis |
| Q35555003 | Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression |
| Q37148403 | MRI-detected osteitis is not associated with the presence or level of ACPA alone, but with the combined presence of ACPA and RF. |
| Q34641300 | Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology |
| Q37350904 | Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort |
| Q36577538 | Mechanisms of disease: Genetic susceptibility and environmental triggers in the development of rheumatoid arthritis |
| Q28475972 | Multiparameter phospho-flow analysis of lymphocytes in early rheumatoid arthritis: implications for diagnosis and monitoring drug therapy |
| Q39186261 | Novel multiplex technology for diagnostic characterization of rheumatoid arthritis |
| Q34559803 | Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? |
| Q42134670 | Onset of polyarticular juvenile idiopathic arthritis with both anti-cyclic citrullinated peptide antibodies and rheumatoid factor in a 3-year-old girl |
| Q34664095 | PADI4 and HLA-DRB1 are genetic risks for radiographic progression in RA patients, independent of ACPA status: results from the IORRA cohort study |
| Q40329877 | Pathogenic role of antibodies to citrullinated proteins in rheumatoid arthritis |
| Q39838852 | Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria |
| Q36951050 | Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors |
| Q36329372 | Predictive value of autoantibodies from anti-CCP2, anti-MCV and anti-human citrullinated fibrinogen tests, in early rheumatoid arthritis patients with rapid radiographic progression at 1 year: results from the ESPOIR cohort |
| Q36955351 | Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project |
| Q35605424 | Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial |
| Q37563990 | Prognostic factors in rheumatoid arthritis in the era of biologic agents. |
| Q36993230 | Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study |
| Q91826148 | Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients |
| Q35637041 | Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset |
| Q38952206 | Reductions in radiographic progression in early RA over 25-years: Changing contribution from RF in 2 multi-centre UK inception cohorts. |
| Q33915665 | Relationship between time-integrated disease activity estimated by DAS28-CRP and radiographic progression of anatomical damage in patients with early rheumatoid arthritis |
| Q86313523 | Resistin in inflammatory and degenerative rheumatologic diseases. Relationship between resistin and rheumatoid arthritis disease progression |
| Q92318385 | Rheumatoid arthritis-relevant DNA methylation changes identified in ACPA-positive asymptomatic individuals using methylome capture sequencing |
| Q39091666 | Rheumatoid factor and antibodies against citrullinated peptides in Moroccan patients with rheumatoid arthritis: association with disease parameters and quality of life |
| Q35638299 | Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis |
| Q37358983 | Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexate |
| Q34897056 | Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis |
| Q36027446 | Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate |
| Q37690729 | Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort |
| Q42560891 | Smoking and nicotine exposure delay development of collagen-induced arthritis in mice |
| Q37689716 | Smoking in combination with antibodies to cyclic citrullinated peptides is associated with persistently high levels of survivin in early rheumatoid arthritis: a prospective cohort study |
| Q55267199 | Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis. |
| Q38166204 | Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases |
| Q43164202 | Survivin co-ordinates formation of follicular T-cells acting in synergy with Bcl-6. |
| Q37280952 | The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases |
| Q30720251 | The Effect of Socioeconomic Class and Immigrant Status on Disease Activity in Rheumatoid Arthritis: Data from BARFOT, a Multi-Centre Study of Early RA. |
| Q41228105 | The Frequency of anti-CCP antibodies in patients with rheumatoid arthritis and psoriatic arthritis and their relationship with clinical features and parameters of angiogenesis: A comparative study |
| Q28395318 | The Role of Posttranslational Protein Modifications in Rheumatological Diseases: Focus on Rheumatoid Arthritis |
| Q58234648 | The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor |
| Q36805269 | The association of anti-CCP antibodies with disease activity in rheumatoid arthritis |
| Q86414594 | The diagnostic utility of matrix metalloproteinase-3 and high-sensitivity C-reactive protein for predicting rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-negative patients with recent-onset undifferentiated arthritis |
| Q35636615 | The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis |
| Q51026091 | The fibrin-derived citrullinated peptide β60-74Cit₆₀,₇₂,₇₄ bears the major ACPA epitope recognised by the rheumatoid arthritis-specific anticitrullinated fibrinogen autoantibodies and anti-CCP2 antibodies. |
| Q47246159 | The impact of smoking on disease activity, disability, and radiographic damage in rheumatoid arthritis: is cigarette protective? |
| Q33563097 | The relationship of antibodies to modified citrullinated vimentin and markers of bone and cartilage destruction in rheumatoid arthritis. |
| Q55689191 | The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy. |
| Q34395284 | The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register |
| Q35107327 | The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis. |
| Q26744033 | Therapeutic implications of autoantibodies in rheumatoid arthritis |
| Q33918379 | Time-averaged disease activity fits better joint destruction in rheumatoid arthritis. |
| Q37147818 | Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs |
| Q37851001 | Unresolved issues in biologic therapy for rheumatoid arthritis |
| Q27014889 | Updating the OMERACT filter: implications for imaging and soluble biomarkers |
| Q46274578 | Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression |
| Q52854962 | Use of prognostic markers in early rheumatoid arthritis to identify patients at risk of destructive disease. |
| Q81575718 | [Early diagnosis of rheumatoid arthritis] |
Search more.